Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity

Novo Nordisk, Europe’s largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.